This legislation aims to enhance the development and accessibility of psychedelic drugs, particularly ibogaine, to address critical mental health issues in the United States, including addiction and trauma-related disorders. By providing new treatment options, the bill seeks to improve mental health outcomes and potentially save lives. Central to the legislation is the establishment of a National Health Priority Voucher Pilot Program, which will expedite the review of drug applications that meet urgent health needs.